Mitomycin 0.04% eye drops
Requires a prescription from a doctor or prescriber
Group of antibiotics
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Mitomycin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Mitomycin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(9)
Bladder cancer: diagnosis and management (NG2)
Bladder cancer (QS106)
Glaucoma: diagnosis and management (NG81)
Trabeculectomy with a biodegradable collagen matrix implant for glaucoma (HTG656)
Synergo for non-muscle-invasive bladder cancer (HTG601)
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (HTG499)
Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (HTG470)
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (HTG487)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · Randomised trials: 28 · 1976–2026
Showing the 50 most relevant studies, sorted by most relevant.
A. Böhle, D. Jocham, P. Bock
The Journal of urology, 2003
Per‐Uno Malmström, Richard Sylvester, David Crawford, et al.
European Urology, 2009
- Adjuvants, Immunologic
- Administration, Intravesical
- Antibiotics, Antineoplastic
Andreas Böhle, P.R. Bock
Urology, 2004
- Adjuvants, Immunologic
- Administration, Intravesical
- Antibiotics, Antineoplastic
R. James
Lancet, 1996
R.D. James, Rob Glynne‐Jones, Helen Meadows, et al.
The Lancet Oncology, 2013
- Antineoplastic Combined Chemotherapy Protocols
- Anus Neoplasms
- Carcinoma, Squamous Cell
T. O'brien, E. Ray, Rajinder Singh, et al.
European urology, 2011
J. Nabholtz, H. Senn, W. Bezwoda, et al.
Journal of Clinical Oncology, 1999
- Docetaxel
- Analysis of Variance
- Antineoplastic Agents
P. Ross, M. Nicolson, D. Cunningham, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002
- Antineoplastic Combined Chemotherapy Protocols
- Cisplatin
- Esophageal Neoplasms
Philip Chen, Reginald G. Ariyasu, VENU KAZA, et al.
American Journal of Ophthalmology, 1995
- Administration, Topical
- Age Factors
- Conjunctiva
J. Au, R. Badalament, M. Wientjes, et al.
Journal of the National Cancer Institute, 2001
- Administration, Intravesical
- Antibiotics, Antineoplastic
- Urinary Bladder Neoplasms
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
8-48 min
Mechanism
Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
8-48 min
Metabolism
Elimination
10%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC)[L12867] - as well as adjunctly to ab externo glaucoma surgeries.
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 555 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01DC03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Mitomycin
Additional database identifiers
Drugs Product Database (DPD)
2195
ChemSpider
5544
BindingDB
50428658
ZINC
ZINC000030726187
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9208
GenAtlas
POR
GeneCards
POR
GenBank Gene Database
S90469
GenBank Protein Database
247307
UniProt Accession
NCPR_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q417625), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.